



देउराली-जनता फर्मास्यूटिकल्स प्रा.लि.

६७९ बुढानिलण्ठ सडक, बांसवारी ३, पोष्ट बक्स: ४२३९, काठमाण्डौ । फोन: ४०९८७७७

मिति: २०७७/०६/०७

FAVIR 200 TABLET (FAVIPRAVIR) : INTRODUCTION

Favipiravir (FAVIR-200 TAB) is an oral antiviral drug which selectively inhibits RNA polymerase to eliminate viral replication. Favipiravir is currently being used in various countries like Japan, USA, Russia, India, Bangladesh, Turkey, Canada Thailand, and many other countries as one of the experimental drugs for COVID-19 caused by novel coronavirus SARs-COV-2. Favipiravir is an effective molecule for the management of COVID-19 in mild to moderate cases. There are many recommendations made by global authorities for the use of Favipiravir in the treatment of mild to moderate cases of COVID -19 under Emergency authorization as the molecule is a safe oral product, available at present.

This drug was initially manufactured and approved by Japan in 2014 and used in various viral epidemic cases in humans including sever Influenza. Favipiravir has been investigated for the treatment of life threatening conditions such as Ebola virus, Lassa virus and recently COVID-19 infections. So far the drug has shown to be effective in third phase of clinical trial carried out in different countries around the world. Many other countries are using Favipiravir in the management of mild to moderate cases of COVID-19 infection following the approval given by the Health Regularity Authorities in their respective countries for Emergency Use. Recently, Favipiravir has been approved by Russian regulatory authority as a prescription drug for the management of COVID-19. Before that, in India and Bangladesh, their regulatory authorities have approved its use as an emergency molecule for the management of COVID-19.

All the preclinical and clinical studies have already established the Favipiravir as a safe molecule for human consumption. The major advantages of Favipiravir are that it's administered orally and that it can be given in patients who are symptomatic but not ill enough to be treated in intensive care unit. As most COVID-19 patients (85%) have mild to moderate symptoms treated at home, this drug could potentially be used in large numbers of patients. As with any antivirals, it is recommended that Favipiravir should be administered early after the PCR positive test & onset of symptoms for it to be effective in reducing viremia (viral load). Its role in potentially shortening the duration of viral shedding could also have an epidemiological impact as it could reduce viral transmission at home and in the community. Recent study outcomes have shown that Favipiravir may slow/stop pneumonia progression in patient with COVID-19 infection. The most important feature of FAVIR-200 TAB as an antiviral agent is the apparent lack of generation of Favipiravir-resistant viruses. Favipiravir alone maintains its therapeutic efficacy in an influenza pandemic or an epidemic lethal RNA virus infection.

All the preclinical and clinical studies have already established as a safe molecule for human consumption and all the observed adverse effects are minor and manageable. In conclusion, FAVIR-200 TAB may emerge as a valuable drug in the management of mild to moderate symptomatic cases of SARS-CoV-2–infected population and possibly bring down the mortality cases in Nepal. Going through its advantages, Deurali-Janta Pharmaceuticals have been rigorously working day in and out to avail the molecule among our people for the last 6 months in this pandemic situation. Deurali-Janta Pharmaceuticals family is privileged and feel proud to announce the availability of the molecule under strict supervision & as outlined by the Government Authorities.